Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

Clinical trial NCT04284228 · UNKNOWN

Trial details

NCT number: NCT04284228
Sponsor: NexImmune Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

Start date: 2020-02-20
Primary completion: 2024-10-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.